GLP-1 Medications, Explained: What They Are, How They Work, and What to Know

GLP-1 stands for glucagon-like peptide-1, a hormone released by the intestine in response to eating. It helps coordinate signals involved in insulin release, glucagon secretion, appetite and digestion. Naturally occurring GLP-1 is short-lived. Prescription GLP-1 receptor agonists are designed to activate this pathway for longer than the body’s own hormone.

GLP-1 receptor agonists help the body release insulin when glucose levels are elevated and reduce inappropriate glucagon secretion. They also act on appetite and fullness pathways, so some people feel satisfied with smaller meals. These medications can delay stomach emptying, especially around treatment initiation; that effect may contribute to gastrointestinal symptoms and can affect the timing or absorption of certain oral medicines. They do not simply “burn fat” or guarantee weight loss.

Semaglutide is a GLP-1 receptor agonist. Wegovy is a semaglutide brand with FDA-approved weight-management uses; Ozempic and Rybelsus are semaglutide brands whose indications differ. Tirzepatide activates both GIP and GLP-1 receptors. Zepbound has FDA-approved weight-management uses, while Mounjaro has a different approved indication. A shared ingredient does not mean that brand names, doses, formulations, indications, or instructions are interchangeable. Eligibility and the appropriate product should be determined from current labeling and the individual’s health needs.

Large clinical trials show that some FDA-approved GLP-1-based medicines can produce clinically meaningful weight reduction when combined with nutrition, activity and behavioral support. Results differ across medicines, doses, trial populations and individuals. Some medicines also have approved uses for conditions beyond weight management, but benefits established for one product or patient population should not automatically be claimed for every GLP-1 medicine or compounded formulation. Focus on sustainable health goals, not a guaranteed number on the scale.

For adult chronic weight management, clinicians commonly assess body mass index (BMI), weight-related health conditions and the broader medical picture. A BMI of 30 or higher, or 27 or higher with a weight-related condition, is a common starting point under several FDA-approved weight-management indications; each product’s exact criteria may differ. BMI alone does not settle whether treatment is appropriate. Medical history, prior efforts, preferences, pregnancy considerations, potential risks, current medicines and cost all affect the decision.

Nausea, vomiting, diarrhea, constipation and abdominal discomfort are common, especially as treatment begins or doses change. More serious concerns described in prescribing information include pancreatitis, gallbladder disease, severe gastrointestinal symptoms, dehydration-related kidney injury and allergic reactions. GLP-1-based medicines can increase low-blood-sugar risk when combined with insulin or certain diabetes medicines. Some products are not recommended for severe gastroparesis. Persistent severe abdominal pain, inability to keep fluids down or symptoms of an allergic reaction require prompt medical evaluation. This is not an exhaustive list: the precise warnings depend on the prescribed product.

Several semaglutide and tirzepatide products carry boxed warnings about thyroid C-cell tumors observed in rodents; whether this occurs in humans is unknown. These products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Weight-loss medicines should not be used during pregnancy; discuss plans for pregnancy and breastfeeding in advance. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives around initiation and dose increases; its labeling specifies temporary additional or alternative contraception. Delayed gastric emptying may also affect certain oral medicines. Tell the clinician about every prescription, over-the-counter medicine and supplement, especially diabetes therapy.

FDA-approved products have undergone FDA review for safety, effectiveness and manufacturing quality for their approved uses. Compounded medicines are not FDA-approved and do not receive that same premarket review. Compounding may be appropriate only under applicable legal requirements and when a patient’s medical needs cannot be met by an FDA-approved drug. The FDA has warned about dosing errors, unapproved salt forms of semaglutide, fraudulent products and adverse events involving compounded GLP-1 medicines. Do not assume a compounded preparation is equivalent to an approved brand or that availability alone establishes legality or safety. Ask whether a product is FDA-approved, why a compounded option is being considered, and which licensed pharmacy will dispense it.

Medication may be a useful tool, but it does not replace balanced nutrition, adequate protein, strength-building activity, sleep or regular follow-up. Rapid or substantial weight loss can include some loss of lean mass, so maintaining muscle function deserves attention. Discuss practical meals, hydration, resistance training and realistic progress measures with the care team. Many people regain some weight after stopping weight-management medication, making long-term planning important.

A thoughtful starting visit reviews goals, relevant medical and family history, current medicines, side-effect risks, treatment preferences and any indicated tests. The clinician explains available options, approved versus compounded status when relevant, medication instructions, costs and follow-up. If a medicine is prescribed, dosing changes and monitoring should follow the specific treatment plan rather than online schedules or advice from social media. Do not combine GLP-1-based medicines or adjust doses without clinician guidance.

This guide is a starting point, not a substitute for personalized medical advice. Explore Pinnacle’s related education on what to expect when starting a GLP-1 medication, medication comparisons, digestive health and treatment planning. Verify live article titles and links before adding internal cross-links. For an individualized conversation, ask the care team about benefits, alternatives, contraindications, medication source and follow-up.